Iron Sulfate Supplementation Decreases Zinc Protoporphyrin to Heme Ratio in Premature Infants - 10/08/11
Reprint requests: Sandra Juul, MD, PhD, Department of Pediatrics, Division of Neonatology, University of Washington Box 356320, Seattle, WA 98195.See editorial, p 8.
Abstract |
Objectives |
To test the utility of zinc protoporphyrin to heme ratio (ZnPP/H) as an indicator of iron status in premature infants and to evaluate the effect of oral iron supplements on oxidative injury. We hypothesized that iron sulfate supplementation would decrease the ZnPP/H in preterm infants.
Study design |
Infants eligible for this prospective study were: hospitalized, 24 to 32 weeks of gestation, 7 to 60 days old, feeding ≥ 70mL/kg/d, with a ZnPP/H ≥ the mean for age. Iron dose was determined by the ZnPP/H. Iron status and oxidative injury were evaluated at study entry and completion. Concurrent control subjects met entry criteria but were not enrolled and were not treated with iron during the study interval. Statistical evaluation included repeated measures analysis of variance and Z-score conversions.
Results |
Entry ZnPP/H of iron-treated subjects (n = 16) and control subjects (n = 16) were not different. The ZnPP/H of iron-treated infants was lower at study end (P < .05) but did not change in control infants. Iron treatment (3 to 12 mg/kg/day) was not associated with changes in conventional measures of iron status nor in measures of oxidative injury.
Conclusions |
Iron sulfate supplementation (3-12 mg/kg/d) decreases ZnPP/H, is tolerated, and is not associated with increased oxidative injury.
Le texte complet de cet article est disponible en PDF.Mots-clés : CGA, GA, NICU, sTfR, SD, TIBC, ZnPP/H
Plan
| Supported by a grant from The Gerber Foundation. A portion of this work was conducted through the Clinical Research Center Facility at the University of Washington and supported by the National Institutes of Health, Grant M01-RR-00037. |
Vol 148 - N° 1
P. 44-48 - janvier 2006 Retour au numéro
Article précédent
- Clinical Responses of Patients with Kawasaki Disease to Different Brands of Intravenous Immunoglobulin
- Ming-Han Tsai, Yhu-Chering Huang, Meng-Hsiu Yen, Chung-Chen Li, Cheng-Hsun Chiu, Pen-Yi Lin, Tzou-Yien Lin, Luan-Yin Chang
- On the move?
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?